Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Jiangsu Hengrui Pharmaceuticals is a China-based innovative pharmaceutical company headquartered in Lianyungang, Jiangsu Province. Founded in 1970. Revenue of RMB 31.63 billion (USD 4.45 billion) in 2025, with 20,000+ employees including 5,600+ R&D personnel, 10+ manufacturing bases, and 14 global R&D centers.

Business Overview

Jiangsu Hengrui Pharmaceuticals represents the pinnacle of China's pharmaceutical industry transformation. Once known primarily as a generic drug manufacturer, Hengrui has undergone a remarkable metamorphosis into a globally competitive innovative pharmaceutical company. The numbers tell the story: in 2025, innovative drug sales reached RMB 16.34 billion, representing 58.3% of total drug revenue — a historic crossover point. The company's total revenue grew 13% to RMB 31.63 billion while net profit surged 21.8% to RMB 7.72 billion, demonstrating the superior economics of innovative drugs compared to generic products.

Hengrui's R&D intensity is extraordinary by any global standard. The company invested RMB 8.72 billion in research and development in 2025 — an impressive 27.6% of total revenue — supporting a pipeline of over 100 clinical-stage drug candidates across 14 global R&D centers staffed by 5,600+ scientists. This investment paid off handsomely with 7 new Class 1 innovative drug approvals during the year. More importantly, Hengrui's drugs are increasingly gaining international validation: 5 overseas licensing-out deals in 2025 generated RMB 3.39 billion in licensing revenue, proving that Chinese-originated innovative pharmaceuticals can compete on the global stage.

Key Strengths

First, Hengrui's R&D investment intensity at 27.6% of revenue ranks among the highest in global pharma, funding one of the industry's deepest oncology-focused pipelines. Second, the successful transition from generics to innovative drugs — with innovative products now contributing 58.3% of pharmaceutical revenue — demonstrates exceptional strategic execution. Third, the company's ability to secure 5 major international licensing-out deals in a single year validates the global competitiveness of its R&D output. Fourth, Hengrui's vertically integrated manufacturing capability from API synthesis to finished dosage forms provides quality and cost control advantages. Fifth, its dominant position in China's oncology market provides a massive domestic revenue base to fund continued global expansion.

Challenges & Outlook

Hengrui's growth trajectory faces headwinds from China's Volume-Based Procurement (VBP) program, which continues to compress pricing on the legacy generic portfolio. While innovative drug growth is rapidly outpacing generic declines, the transition requires careful management. International commercial presence remains limited to licensing partnerships rather than direct market operations, constraining brand visibility in Western markets. However, with over 100 clinical-stage assets, a demonstrated track record of global licensing success, and the financial firepower from China's vast domestic market, Hengrui is exceptionally well-positioned to emerge as China's first truly global innovative pharmaceutical company.

VerityRank Score

Jiangsu Hengrui Pharmaceuticals achieves a VerityRank Score of 89/100, reflecting its market leadership, revenue scale, R&D capabilities, global manufacturing footprint, and competitive positioning within the pharmaceutical industry.